Heavy Metals in Herbal Supplements: Why EU Concentration Limits Don't Guarantee Health Canada Compliance

A consignment of dried ashwagandha root extract arrives from an Indian supplier with a COA showing full compliance with European Pharmacopoeia limits: lead at 3.2 mg/kg, arsenic at 1.4 mg/kg, mercury below detection, cadmium at 0.4 mg/kg. The European brand’s quality team signs it off. Six months later, the Health Canada NPN submission for the finished capsule product receives a safety information request — and the brand has no satisfactory answer ready.

This scenario plays out more often than it should. The problem isn’t that the supplier’s data is wrong. It’s that European brands routinely use concentration-based limits from the Ph.Eur. as a proxy for global compliance. Health Canada doesn’t work that way.

How the European Pharmacopoeia Frames Heavy Metal Limits

The Ph.Eur. general monograph for medicinal plants and herbal drug preparations sets maximum limits as concentrations in the dried raw material. The widely applied values for herbal drugs are:

• Lead (Pb): 5.0 mg/kg
• Arsenic (As): 2.0 mg/kg
• Mercury (Hg): 0.1 mg/kg
• Cadmium (Cd): 1.0 mg/kg

These figures are expressed as milligrams of metal per kilogram of dry herb, assessed at the raw material stage. The regulatory logic is straightforward: control contamination at the source, and downstream consumer risk is managed. Commission Regulation (EC) No 1881/2006 — which sets maximum levels for certain contaminants in foodstuffs — reinforces this concentration-based model for food supplements sold within the EU. EMA/HMPC guidelines for traditional herbal medicinal products apply a comparable framework for licensed products.

France’s DGCCRF references Ph.Eur. limits in its guidance for botanically-derived food supplements. So for European brands operating domestically, this model has regulatory coherence. The difficulty arises when the same logic travels to a market with a fundamentally different risk model — and Canada is exactly that market.

Health Canada’s Daily Intake Framework

Health Canada’s approach to heavy metals in natural health products is grounded in daily intake calculations, not raw material concentrations. The Natural Health Products Regulations (SOR/2003-196) require that submissions demonstrate the safety of each ingredient and finished product. Health Canada’s guidance documents for NHP applications — published through the Natural and Non-prescription Health Products Directorate (NNHPD) — make clear that heavy metal safety must be evaluated against the recommended daily intake of the finished product, not the concentration in the raw ingredient.

The framework draws on provisional tolerable daily intake (PTDI) values established by JECFA — the Joint FAO/WHO Expert Committee on Food Additives. Health Canada’s accepted heavy metal limits for NHPs are expressed as micrograms per day:

• Lead: 10 µg/day
• Arsenic (inorganic): 15 µg/day
• Mercury: 20 µg/day
• Cadmium: 6 µg/day

The critical variable is per day. The permissible concentration in your finished product is a direct function of how much product a consumer takes daily. A 500 mg capsule dose and a 3,000 mg daily serving of a high-dose botanical powder face dramatically different tolerance windows — even from the same raw material.

Take that ashwagandha extract. A typical evidence-based dosing protocol calls for 600 mg to 1,200 mg of root extract per day. Using 1,000 mg as a mid-range reference: Health Canada’s lead limit of 10 µg/day divided by 1,000 mg product gives a permissible concentration of 10.0 mg/kg. At that dose, the EU’s 5.0 mg/kg limit is actually the more conservative standard.

But scale to a high-dose powder product at 3,000 mg/day — common for bulk botanical powders sold in European health food retail:

10 µg/day ÷ 3,000 mg = 0.0033 µg/mg = 3.3 mg/kg

A raw material testing at 4.1 mg/kg lead passes the European Pharmacopoeia limit. The supplier COA shows a clean result. But that same raw material, at 3,000 mg/day, delivers 12.3 µg of lead daily — 23% above Health Canada’s acceptable limit. The NPN submission fails the safety assessment, and the brand only finds out months after the application was filed.

Where European Brands Get Caught

The concentration-versus-intake divergence creates specific traps that appear repeatedly in NPN submissions from European exporters.

High-dose powder products compress the tolerance window. Bulk botanicals — ashwagandha, turmeric, moringa, spirulina, maca root — are routinely consumed at 2,000 to 5,000 mg per day in powder and multi-gram capsule formats. At those dose levels, even raw materials well within Ph.Eur. limits can fail Health Canada’s cadmium (6 µg/day) and inorganic arsenic (15 µg/day) thresholds, particularly for soil-grown herbs from mineral-rich agricultural regions.

Speciation matters — and most EU COAs don’t provide it. Total arsenic and inorganic arsenic represent entirely different toxicological profiles. Marine-derived botanicals — spirulina, chlorella, certain red algae — often contain arsenobetaine and arsenocholine (organic arsenic species), which are largely non-toxic. Health Canada evaluates inorganic arsenic specifically. The vast majority of EU supplier COAs report total arsenic only, because Ph.Eur. limits are written against the total figure. Submitting a total arsenic COA to Health Canada as safety evidence is scientifically incomplete and will almost certainly trigger a safety information request, delaying NPN review by three to six months — sometimes longer during periods of high submission volume.

Soil-grown Ayurvedic and TCM herbs are elevated-risk categories. Ashwagandha, bacopa, shatavari, guduchi, and many traditional Chinese medicine herbs are cultivated in mineral-rich soils across India, China, and Southeast Asia. Multiple independent market surveys — including analyses conducted under the USP’s Botanical Adulterants Prevention Program — have identified elevated lead and arsenic in commercially traded samples from these origins. An EU-focused COA showing compliance with Ph.Eur. limits doesn’t surface latent risk if the raw material is sitting at 4.5 mg/kg lead and the formulation calls for a 2,500 mg daily serving.

Multi-ingredient formulas hide cumulative exposure. A product blending four botanical extracts might have each ingredient testing below Ph.Eur. limits. But Health Canada evaluates total daily intake across the finished formula. If all four ingredients contribute lead to the daily dose, a brand needs to sum those contributions and check the total against 10 µg/day. European quality systems built around per-ingredient raw material release testing rarely capture this additive picture — and it’s rarely checked before the NPN submission goes in.

Building a Testing Strategy That Satisfies Both Frameworks

None of this requires choosing between markets. It requires designing testing protocols that gather enough data to calculate compliance under both models — ideally before a product is formulated, not after it’s filed.

Step 1: Specify ICP-MS as the required analytical method. Inductively coupled plasma mass spectrometry provides the sensitivity and elemental specificity that both Ph.Eur. compliance testing and Health Canada submissions require. Some European suppliers still offer heavy metal screening by colorimetric methods or ICP-OES, which may be adequate for Ph.Eur. pass/fail purposes but lack the detection limits and precision needed for Health Canada’s daily intake calculations, particularly for mercury and inorganic arsenic at low concentrations.

Step 2: Add speciated arsenic to every botanical raw material COA. Request inorganic arsenic as a distinct line item — separate from total arsenic. ISO 17025-accredited laboratories offering speciation by HPLC-ICP-MS can distinguish inorganic As(III) and As(V) from organic arsenobetaine and arsenocholine. For marine botanicals, this test routinely drops the “arsenic burden” from a concerning total figure to a negligible inorganic fraction and removes a significant NPN submission risk. For soil-grown herbs, it may confirm what you’d rather know before filing.

Step 3: Run the daily intake calculation at the formulation stage. Before finalising a product formula, take the heavy metal concentration from each raw material COA, multiply by the per-ingredient daily dose in milligrams, sum across all ingredients, and compare the totals against Health Canada’s µg/day limits. This calculation takes less than an hour with COA data already in hand. It can redirect a reformulation or supplier switch decision before the product is locked — a far cheaper intervention than a failed submission.

Step 4: Build dual-framework documentation for the submission dossier. For NPN applications, include a dedicated heavy metals safety assessment that explicitly presents both the Ph.Eur. concentration data (as evidence of raw material quality) and the daily intake calculation per Health Canada’s NNHPD framework. Reviewers who have processed European submissions before know the concentration-versus-intake gap exists. Presenting both frameworks proactively demonstrates regulatory literacy and materially reduces the probability of a safety query letter.

Our team works with European brands through exactly this kind of pre-submission safety assessment, coordinating with ISO 17025-accredited partner laboratories in Canada and the EU to produce test reports that are both scientifically sound and formatted for NNHPD review.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• Health Canada NHP Testing for European Brands — Androxa provides ISO 17025-accredited natural health product testing in Canada, with COA formats designed for Health Canada NPN submission review.
• ICP-MS Heavy Metal & Botanical Ingredient Testing — Qalitex Laboratories offers elemental analysis and speciated arsenic testing for supplement brands entering North American markets.